Full Range Spectral Domain Anterior Segment OCT Scanner

全范围谱域眼前节 OCT 扫描仪

• 批准号: 7219581
• 负责人: Eric L. Buckland
• 金额: $ 15.5万
• 依托单位: BIOPTIGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-07 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7219581
• 关键词: Animal Experimentation; Animals; Anterior; Applied Research; Arts; Businesses; Class; Clinical; Collaborations; Complex; Computer software; Cornea; Depth; Diagnosis; Endothelium; Equus caballus; Excision; Exhibits; Glaucoma; Hand; Human; Image; Infant; Interferometry; Life; Marketing; Microscope; Morphologic artifacts; Mus; Noise; Operating System; Operative Surgical Procedures; Optical Coherence Tomography; Optics; Patients; Phase; Range; Rate; Research; Resolution; Retinal; Scanning; Signal Transduction; Small Animal Imaging Systems; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Specialist; Speed; Standards of Weights and Measures; Surface; System; Technology; Three-Dimensional Image; Three-Dimensional Imaging; Time; Tissues; Universities; base; corneal epithelium; design; improved; innovation; millimeter; new technology; novel strategies; pre-clinical research; prototype; size

DESCRIPTION (provided by applicant): In this Phase I Small Business Innovative Research application, Bioptigen Inc. proposes to prototype a portable, handheld cornea and anterior segment optical coherence tomography (CAS-OCT) scanner for use in clinical and applied research applications. OCT is a relatively new technology for ophthalmic imaging, which uses low-coherence interferometry to obtain cross-sectional images in living tissues with micron-scale resolution noninvasively. OCT systems based on the original time-domain interferometry technology have been successfully demonstrated for human retinal and anterior segment imaging at 830nm and 1300nm wavelengths, respectively, however the slower image acquisition rate and lower signal-to-noise ratio of the older technology places severe constraints on the range of subjects which can be successfully imaged. In order to immobilize patients for long acquisition times, retinal and anterior segment OCT imagers commercialized to date have been built into standard tabletop slit-lamp biomicroscope designs. The resulting systems are bulky and limit the range of potential subjects to cooperative humans who can sit upright and fixate well for several seconds. In the last few years, Fourier domain OCT (FDOCT) technology has emerged as a superior alternative to time-domain OCT, exhibiting improved image acquisition speed and robust system design. The increased image acquisition speed opens the possibility for the first time for ophthalmic OCT imaging with handheld probes, and the robust design potential of FDOCT enables the implementation of truly portable systems. Bioptigen, Inc., a startup company affiliated with Duke University, has marketed state-of-the- art retinal FDOCT systems operating at 830nm wavelength using both conventional and handheld delivery optics, and also markets a tabletop microscope-based 1300nm wavelength OCT system for small animal imaging and other pre-clinical research applications. However, due to a limitation intrinsic to FDOCT, both of these systems are limited in imaging depth to less than 4 millimeters, which is insufficient for full-depth anterior segment imaging. In this SBIR Phase I proposal, Bioptigen proposes to adapt their 1300nm OCT and handheld probe technology for high speed, handheld, full-depth anterior segment imaging which will make the benefits of ophthalmic OCT imaging available to a much wider class of subjects, including bedridden and infant human patients, as well as animals of all sizes (from mouse to horse) used in biomedical and veterinary research. In this Phase I Small Business Innovative Research application, Bioptigen Inc. proposes to prototype a portable, handheld cornea and anterior segment optical coherence tomography (CAS-OCT) scanner for use in clinical and applied research applications. This imaging system will be able to image the full depth of the anterior segment (> 6mm) by developing a novel approach to complex conjugate artifact removal.

描述（由申请人提供）：在此第一阶段小型企业创新研究申请中，Bioptigen Inc. 提议制作一款便携式手持式角膜和眼前段光学相干断层扫描 (CAS-OCT) 扫描仪原型，用于临床和应用研究应用。 OCT是一种相对较新的眼科成像技术，它使用低相干干涉测量法以无创方式获取活体组织中微米级分辨率的横截面图像。基于原始时域干涉测量技术的 OCT 系统已成功演示，可分别在 830nm 和 1300nm 波长下进行人体视网膜和眼前节成像，但旧技术较慢的图像采集速率和较低的信噪比带来了严重的问题可以成功成像的对象范围的限制。为了使患者长时间固定不动，迄今为止商业化的视网膜和眼前节 OCT 成像仪已内置于标准桌面裂隙灯生物显微镜设计中。由此产生的系统体积庞大，限制了潜在受试者的范围，仅限于能够坐直并注视几秒钟的合作人类。在过去几年中，傅里叶域 OCT (FDOCT) 技术已成为时域 OCT 的卓越替代方案，展现出改进的图像采集速度和稳健的系统设计。图像采集速度的提高首次为使用手持式探头进行眼科 OCT 成像提供了可能性，而 FDOCT 强大的设计潜力使得实现真正的便携式系统成为可能。 Bioptigen, Inc. 是一家隶属于杜克大学的初创公司，已销售使用传统和手持传输光学器件在 830 nm 波长下运行的最先进的视网膜 FDOCT 系统，并且还销售基于台式显微镜的 1300 nm 波长 OCT 系统，用于小动物成像和其他临床前研究应用。然而，由于FDOCT固有的局限性，这两种系统的成像深度都限制在4毫米以下，这不足以进行全深度眼前节成像。在这项 SBIR 第一阶段提案中，Bioptigen 提议将其 1300nm OCT 和手持式探头技术调整为高速、手持式、全深度眼前节成像，这将使眼科 OCT 成像的优势惠及更广泛的受试者，包括卧床不起的受试者和婴儿患者，以及用于生物医学和兽医研究的各种体型的动物（从小鼠到马）。在这一第一阶段小型企业创新研究应用中，Bioptigen Inc. 提议制作一款便携式手持式角膜和眼前段光学相干断层扫描 (CAS-OCT) 扫描仪原型，用于临床和应用研究应用。通过开发一种去除复杂共轭伪影的新方法，该成像系统将能够对眼前节的整个深度（> 6mm）进行成像。